智通财经APP观察到，自去年11月21日盘中触底36.08港元后，泰格医药股价持续回升，走出了一段近2个月的拉升行 情，并在今年1月15日将股价拉升至最高54.85港元，区间最大涨幅达到52.02%。 但之后，泰格医药股价又迎来近半个月的技术性下跌，于1月28日跌破50港元。此时公司股价在技术面上已触及BOLL 线中轨，并有继续下探至下轨位的趋势。不过这一趋势被其在1月29日和30日的两日大涨打断，还将公司股价走势硬 生生"掰回"到企稳回升的形态中。而导致这一盘面变化的根本原因或在于泰格医药披露的2025年年报业绩预告。 "盈警"背后，以投养研策略获市场认可 1月29日盘后，泰格医药披露了其2025年年报业绩预告。 近日，泰格医药（300347）(03347)的股价出现了一波明显的止跌反弹的趋势。 在这则"盈利预警"公告中，泰格医药表示，预期公司2025年实现营业收入66.6亿-76.8亿元，同比增长1%至16%;归属于 上市公司股东的净利润为8.3亿-12.3亿元，同比增长105%至204%;归属于上市公司股东的扣除非经常性损益后的净利润 约3.3亿-4.9亿元，同比下降61%至43%。 在公告中，泰格医药 ...

Core Viewpoint - The stock price of Tigermed (03347) has shown a significant rebound after a period of decline, primarily driven by the company's earnings forecast for 2025, which has garnered market attention and investor interest [1][2]. Group 1: Stock Performance - Tigermed's stock price has rebounded from a low of 36.08 HKD on November 21 last year to a peak of 54.85 HKD on January 15, marking a maximum increase of 52.02% [1]. - Following a technical decline, the stock price fell below 50 HKD but rebounded sharply on January 29 and 30, indicating a stabilization in its price trend [1]. - The stock price jumped to 56.25 HKD the day after the earnings forecast was released, reflecting strong buying interest from investors [3]. Group 2: Earnings Forecast - Tigermed's earnings forecast for 2025 predicts revenue between 6.66 billion and 7.68 billion CNY, representing a year-on-year growth of 1% to 16% [2]. - The net profit attributable to shareholders is expected to be between 830 million and 1.23 billion CNY, showing a significant increase of 105% to 204% [2]. - However, the growth in net profit is largely attributed to non-recurring gains, which are expected to be between 500 million and 740 million CNY, indicating that the core business did not drive this growth [2]. Group 3: Market Sentiment and Institutional Response - Following the earnings forecast, Goldman Sachs adjusted its profit forecasts for Tigermed, lowering estimates for 2025 while slightly increasing those for 2026 and 2027, and raised the target price for its H-shares to 66.4 HKD [3]. - UBS also set a target price of 57.1 HKD for Tigermed, emphasizing the importance of monitoring new order prices and management guidance for 2026 [3]. - The trading activity in the secondary market indicates a strong buying sentiment, with a significant increase in trading volume following the earnings announcement [3]. Group 4: Industry Trends - The domestic healthcare financing market has shown signs of recovery, with a 22% year-on-year increase in financing amounts in the first three quarters of 2025, indicating a shift towards more substantial clinical investments [10]. - The approval rates for innovative drug applications have improved, with a 96.5% approval rate for INDs, suggesting a more favorable regulatory environment for clinical projects [10][11]. - The demand for clinical CRO services is expected to rise as companies increase their clinical trial investments, benefiting leading firms in the industry [11]. Group 5: Business Model and Strategy - Tigermed's strategy of "investing to support research" has proven advantageous, with new order volumes expected to grow significantly compared to the previous year [11]. - This model is not unique to Tigermed, as many CRO companies are adopting similar strategies to expand their market presence [12]. - However, this business model carries inherent risks, as fluctuations in industry conditions can impact both the core CRO business and the investment returns, leading to increased stock volatility [12].